Creso Pharma Limited (ASX:CPH) has secured an additional A$500k in funding from Obsidian Global GP, LLC via the issuance of convertible notes.
The Company will also issue 12,857,143 Collateral Shares and 22,000,000 listed options trading on the ASX under the code "CPHO" with an A$0.25 strike price.
This funding is in addition to recent shareholder approval of ~A$2m of director participation in prior placements.
CEO and MD Mr William Lay says they're pleased to have further progressed their relationship with Obsidian and that they remain well positioned to deliver value to shareholders.